NCT07484022 2026-03-19
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Generate Biomedicines
Phase 1 Not yet recruiting
Clinical Trials
11 trialsNCT07322263 2026-03-17
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
Phase 2 Not yet recruiting
NCT07460245 2026-03-10
AVESEC
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Not yet recruiting
NCT07439120 2026-02-27
Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase EARLY_PHASE1 Not yet recruiting
NCT07421700 2026-02-19
A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Pfizer
Phase 1/2 Not yet recruiting
NCT07413523 2026-02-17
ASTRA
Istituto Clinico Humanitas
Phase NA Not yet recruiting
NCT07386847 2026-02-04
A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer
Pfizer
Not yet recruiting
NCT07189793 2025-09-24
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Not yet recruiting
NCT07072637 2025-07-18
Neurological Function in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin-Based Therapy
National Taiwan University Hospital
Not yet recruiting
NCT06994078 2025-05-29
Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase NA Not yet recruiting
NCT06912672 2025-04-08
UMT-UC
Shanghai Epiprobe Biotechnology Co., Ltd.
Not yet recruiting